Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-13T21:59:35.493Z Has data issue: false hasContentIssue false
  • English
  • Français

A Controlled Study of Oral Vigabatrin (ɣ-Vinyl GABA) in Patients with Cerebellar Ataxia

Published online by Cambridge University Press:  18 September 2015

A.M. Bonnet ,
M. Esteguy ,
G. Tell ,
P.J. Schechter ,
J. Hardenberg  and
Y. Agid
A.M. Bonnet
Affiliation:
Clinique de Neurologie et Neuropsychologie Hôpital de la Salpêtrière, Paris, France
M. Esteguy
Affiliation:
Clinique de Neurologie et Neuropsychologie Hôpital de la Salpêtrière, Paris, France
G. Tell
Affiliation:
Merrell Dow Research Institute, Strasbourg, France
P.J. Schechter
Affiliation:
Merrell Dow Research Institute, Strasbourg, France
J. Hardenberg
Affiliation:
Merrell Dow Research Institute, Strasbourg, France
Y. Agid*
Affiliation:
Clinique de Neurologie et Neuropsychologie Hôpital de la Salpêtrière, Paris, France
*
Hôpital de la Salpêtrière, 47, boulevard de l'Hôpital, 75013 Paris, France
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Vigabatrin (ɣ-vinyl GABA; GVG), an irreversible inhibitor of GABA-transaminase, at a daily dose of 2-4 g, and a placebo were each administered orally for 4 months to 14 patients with cerebellar ataxia (9 with Friedreich's ataxia, 5 with olivopontocerebellar atrophy), in a double-blind, placebo-controlled crossover study. For the group as a whole, there was no significant difference between the GVG and placebo periods in any of the parameters of cerebellar symptomatology measured. Individually, one patient showed some improvement after 3 months of treatment with 2 g/day GVG. Tolerance to 4 g/day GVG was poor, whereas 2 g/day was well tolerated. The results suggest that agents which increase central GABA concentrations are not likely to be of benefit to patients with Friedreich's ataxia or olivopontocerebellar atrophy.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 13 , Issue 4 , November 1986 , pp. 331 - 333
Copyright
Copyright © Canadian Neurological Sciences Federation 1986

References

1.Huxtable, RJ, Azari, J, Reisine, T, et al. Regional distribution of amino acids in Friedreich’s Ataxia brains. Can J Neurol Sci 1979; 6: 255–258.CrossRefGoogle ScholarPubMed
2.Jung, MJ, Lippert, B, Metcalf, BW, et al. Ƴ-y-vinyl GABA (4-amino-hex-5-enoic acid), a new selective inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977; 29: 797–802.CrossRefGoogle ScholarPubMed
3.Grove, J, Schechter, PJ, Tell, G, et al. Increased gamma-aminobutyric acid (GABA), homocarnosine and β-alanine in cerebro-spinal fluid of patients treated with gamma-vinyl-GABA. Life Sciences 1981; 28: 2431–2439.CrossRefGoogle ScholarPubMed
4.Schechter, PJ, Hanke, NFJ, Grove, J, et al. Biochemical and clinical effects of gamma-vinyl-GABA in patients with epilepsy. Neurology 1984; 34: 182–186.CrossRefGoogle ScholarPubMed
5.Grove, J, Palfreyman, MG and Schechter, PJ. Cerebrospinal fluid GABA as an index of brain GABA activity. Clin Neuropharmacol 1983; 6: 223–229.CrossRefGoogle ScholarPubMed
6.Rimmer, EM and Richens, A. Double-blind study of Ƴ-y-vinyl GABA in patients with refractory epilepsy. Lancet 1984; 1: 189–190.CrossRefGoogle ScholarPubMed
7.Gram, L, Klosterkov, P and Dam, M. Ƴ-y-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Ann Neurol 1985; 17: 262–266.CrossRefGoogle Scholar
8.De Smet, Y, Mear, JY, Tell, G, et al. Effect of Gamma-vinyl-GABA in Friedreich’s ataxia. Can J Neurol Sci 1982; 9: 171–173.CrossRefGoogle ScholarPubMed
9.Pourcher, E and Barbeau, A. Field testing of an Ataxia scoring and staging system. Can J Neurol Sci 1980; 7: 339–344.CrossRefGoogle ScholarPubMed